Jaagsiekte retrovirus (JSRV) causes ovine pulmonary adenocarcinoma (OPA), a transmissible lung cancer of sheep. The envelope (Env) glycoprotein protein of JSRV functions as a dominant oncoprotein in vitro and in vivo. An SH2 binding domain (YXXM) in the cytoplasmic tail of the JSRV Env is one of the main determinants of viral transformation at least in vitro. In these studies, we report the first in vivo tests of sitespecific mutants of JSRV in their natural host, the sheep. We show that, in vivo, JSRV 21 with the cytoplasmic tail YXXM mutated to DXXM did not cause disease nor detectable infection, indicating that this motif is absolutely required for virus replication and possibly transformation in vivo. In contrast, mutation of the JSRV open reading frame orf X, for which no function has yet been attributed, did not alter the disease induced by JSRV 21 .
Introduction
Jaagsiekte sheep retrovirus (JSRV) is the causative agent of ovine pulmonary adenocarcinoma (OPA), an infectious lung tumor of sheep. The disease is of interest both as a real veterinary problem, and as a potential model for some human lung adenocarcinomas (Perk and Hod, 1982; Mornex et al., 2003) . In recent years we and others have investigated the mechanism of oncogenesis by JSRV using in vitro systems. JSRV itself does not replicate efficiently in cell culture, but expression of the JSRV envelope glycoprotein (Env) is able to morphologically transform various cell lines including rodent fibroblast and epithelial cells, and human lung epithelial cells (Allen et al., 2002; Chow et al., 2003; Danilkovitch-Miagkova et al., 2003; Liu and Miller, 2005; Maeda et al., 2001; Rai et al., 2001) . Thus, JSRV Env appears to function as an oncogene, a unique situation for mammalian oncogenic retroviruses.
We found that the in vitro transforming activity of JSRV Env is dependent on the short cytoplasmic tail of the C-terminal transmembrane (TM) domain. In particular, a single tyrosine at position 590 is critical since mutation of this residue (Y590F, Y590D or Y590A) abolishes transformation in rodent cells (Hull and Fan, 2006) . The Y590 is in the sequence motif YXXM, which if phosphorylated could bind the SH2 domain of the p85 regulatory subunit of phosphatidyl inositol 3-kinase (PI3K). Indeed, constitutive phosphorylation of Akt, a downstream substrate of PI3K, was detected in JSRV-transformed rodent fibroblasts; the phosphorylation was blocked by PI3K inhibitors or mutation of Y590 (Alberti et al., 2002; . However, Y590 has not been found phosphorylated in Env-transformed cells and there is no evidence of p85 binding the JSRV Env. In addition some cell lines such as the chicken fibroblast line DF-1, transformation by JSRV Env does not absolutely require Y590 (Allen et al., 2002) although trans-formation is less efficient (Zavala et al., 2003) . Akt phosphorylation can be detected in vivo in tumors induced by the related enzootic nasal tumor virus (ENTV), but only in some OPA tumors (Zavala et al., 2003; Suau et al., 2006) . Thus the importance of the Y590 residue for JSRV oncogenesis in vivo remains to be determined.
JSRV carries an alternate reading frame within the pol gene, designated orf X (York et al., 1992) . This reading frame is conserved in all exogenous JSRV isolates sequenced to date and also in some of the JSRV-related sheep endogenous retroviruses present in normal sheep Rosati et al., 2000) . Caprine ENTV (ENTV-2) also has an open orf X reading frame, but there are two stop codons in the orf X reading frame of ovine ENTV (ENTV-1) (Cousens et al., 1999) . orf X has an unusual codon usage, which suggests that the putative protein may be expressed at low levels. Weak amino acid similarity of the putative OrfX protein to the adenosine A3 receptor has been noted (Bai et al., 1999) . The Orf X peptide has proven difficult to express in vitro, so it has not been possible to raise antisera that might detect expression of the protein in infected cells or tumors. We detected a 3.2 Kb spliced JSRV RNA in OPA tumors and transiently transfected 293T cells containing the entire orf X reading frame which could be the mRNA for this protein .
We previously generated a mutant molecular clone of JSRV DNA containing two stop codons in the orf X reading frame without altering the amino acids in the overlapping pol frame . In in vitro transformation assays, this mutant gave the same number of transformed foci in NIH-3T3 cells as the parental wild-type JSRV DNA clone . Thus orf X protein does not appear to be involved in the oncogenic properties of JSRV, but this did not rule out effects on virus replication.
Given the lack of an efficient cell culture system for the propagation of JSRV we cannot test in vitro viral mutants. In these studies, we report the first in vivo tests of site-specific mutants of JSRV in their natural host, the sheep. Our previous isolation of an infectious and oncogenic molecular clone of JSRV, and development of methods to prepare infectious virus from it, made this possible (Palmarini et al., 1999a) . In this report, mutants in env (Y590D) and in orf X were studied.
Results

Generation of infectious JSRV mutants in orf X or env
To test the potential importance of the orf X and the Y590 residue of the JSRV Env in oncogenesis in vivo, it was first necessary to generate infectious JSRVs containing mutations in these genes. We previously isolated a complete integrated JSRV provirus (clone 21) from an OPA tumor and showed that placing the viral sequences under control of the highly active human cytomegalovirus (CMV) immediate early promoter allowed production of infectious virus by transient DNA transfection of human 293T cells (Palmarini et al., 1999a) . The availability of this virus allowed us to establish an in vitro infection system for JSRV in sheep choroid plexus (CP) cells and other ovine cell lines (Palmarini et al., 1999b) , although infection was inefficient due to the fact that the JSRV is transcriptionally specific for lung epithelial cell lines, and no ovine lung epithelial lines that retain their differentiation properties exist. In vitro, infectivity could be assessed by infection of CP cells, followed by serial passage of the infected cultures and PCR analyses for JSRV DNA at different passages.
We previously described a mutant form of the CMV-driven JSRV proviral plasmid in which two stop codons were created in the orf X reading frame by single base mutations that did not affect the amino acids in the corresponding parts of the integrase protein (pCMV2JS21Δorf X, Maeda et al., 2001) . We showed that pCMV2JS21Δorf X is capable of transforming NIH-3T3 cells in culture, indicating that the putative orf X protein is not necessary for transformation . We tested if JSRV virus with the orf X mutation is infectious in vitro. JSRV Δorf X was prepared by transient transfection of 293T cells, and then tested for infection of CP cells ( Fig. 1 ). Compared to CP cells infected with wild-type JSRV, similar amounts of JSRV DNA could be detected in cells infected with JSRV Δorf X, even after prolonged passage (23 passages). In contrast, infection of CP cells with heat-inactivated viruses resulted in no PCR amplification products, indicating that the positive PCR signals represented genuine viral infection. These results indicated that orf X protein is not necessary for JSRV replication in vitro, and they provided a means for generation of orf X mutant virus.
We have extensively studied the JSRV Env protein and its role in in vitro transformation of rodent cells (Alberti et al., 2002; Chow et al., 2003; Hofacre and Fan, 2004; Hull and Fan, 2006; Maeda et al., 2003 Maeda et al., , 2005 Zavala et al., 2003) . For the transformation studies, we used a CMV-driven Env expression plasmid derived from pCMV2JS21 that only encodes Env protein, pCMV3ΔGP . Previous site-directed mutagenesis experiments indicated that a YXXM motif (putative binding site for the p85 subunit of phosphatidyl inositol 3-kinase [PI3K]) is essential for efficient transformation in mouse and rat cells (Hofacre and Fan, 2004; Maeda et al., 2005; . In particular, mutation of the YXXM tyrosine residue (Y590F or Y590D) abolished or greatly reduced transformation . To test if these Env mutations allowed production of infectious virus, they were transferred from pCMV3ΔGP to pCMV2JS21, to give the plasmids pCMV2JS21-TMY590F and pCMV2JS21-TMY590D. Mutant viruses were then obtained by transient transfection of the proviral plasmids into 293T cells, and they were then tested for replication in vitro in CP cells as described above. Both mutant viruses were capable of replication in CP cells, as evidenced by positive PCR signals in the infected cultures. However, the PCR signal for JSRV TMY590F was lost after 3-4 cell transfers, while the PCR signal for JSRV TMY590D persisted for the same number of transfers as for cultures infected with wild-type JSRV (N6 transfers). These results indicated that the Y590F mutation in TM reduced infectivity of the virus, while Y590D mutation did not appear to show this defect within the limitations of the assay. Therefore, JSRV TMY590D was chosen for in vivo studies.
Generation and quantification of JSRV stocks
Viral stocks of wild-type and mutant JSRVs were prepared by large-scale transient transfection of 293T cells as described in Materials and methods. Two preparations of wild-type JSRV were generated, one in parallel with JSRV Δorf X for one experiment (JS21-04) and one in parallel with JSRV TMY590D for the other experiment (JS21-03). During the transient transfections, the relative amounts of the wild-type and mutant viruses produced on the different days of harvest were monitored by SDS-PAGE and western blotting for JSRV CA protein (26 kDa) (Fig. 2) . The amount of JSRV Δorf X produced by the transfected cells was similar to that for wild-type JSRV (top panels). On the other hand, the amount of JSRV TMY590D was consistently less than that produced by the wild-type JSRVproducing cultures (ca. ten-fold less, lower panels). Therefore, more transfected cultures and higher degrees of concentration were used to generate the JSRV TMY590D stocks; they were adjusted to the concentration of the wild-type JSRV stock based on western blotting for JSRV CA.
Subsequent to the experimental inoculations, we developed a quantitative RT-PCR assay for JSRV RNA (Cousens et al., in preparation) , and it was applied to the viral inocula as an independent measure of the amounts of virus inoculated. The results indicated that in the first experiment comparing wildtype and TMY590D JSRV, the amounts of viral RNA in the inocula were equivalent; in the second experiment comparing wild-type and Δorf X JSRV, the amount of JSRV Δorf X RNA was approximately five-fold higher than wild-type JSRV RNA (Fig. 2) . Thus fairly well-matched inocula were used in the experiments. All inocula were checked by RT-PCR amplification and sequencing of the regions encompassing the mutations. For the mutant viruses, the expected mutations were detected, and there was no evidence for the presence of wild-type JSRV in the stocks.
In vivo infection with JSRV TMY590D
In the first experiment, twenty newborn (1-7 days old) lambs from an OPA-free flock were inoculated intra-tracheally with wild-type JSRV (stock JS21-03), and the same number of animals were inoculated with an equivalent amount of JSRV TMY590D (stock Y590D-03) ( Table 1) . Sixteen of the wildtype JSRV-inoculated animals appeared to show early signs of OPA between 6 and 12 weeks p.i. and were sacrificed and necropsied. OPA was confirmed by histopathology in 14 out of the sixteen animals. The remaining four animals were sacrificed and analyzed at 9 months p.i., and three of them were confirmed to have OPA. Thus in total at least 17/20 of animals inoculated with the cloned JSRV 21 stock developed OPA by 9 months.
None of the animals inoculated with JSRV TMY590D showed symptoms of OPA over the course of the experiment (9 months). One animal was sickly and was euthanized at 3 weeks of age. Eight animals were sacrificed and necropsied at 6 months p.i., and the remainder at 9 months. None of the animals showed evidence of OPA upon histological examination. This would be consistent with the TMY590D mutation abolishing in vivo oncogenicity for the virus. To test if JSRV TMY590D could replicate in vivo, we tested blood at various times post-inoculation and mediastinal lymph nodes at postmortem for the presence of viral DNA by PCR (Salvatori et al., 2004) . We have previously found that low levels of infected cells in the blood can be detected by PCR in animals experimentally inoculated with JSRV (Holland et al., 1999; Palmarini et al., 1996; Salvatori et al., 2004) and this can be taken as an indicator of productive in vivo infection. Likewise, some blood samples from animals naturally-infected with JSRV test positive by PCR, but this is highly variable when longitudinal samples from the same animal are tested (D. Salvatori PhD thesis; Caporale et al., 2005; De las Heras et al., 2005; Gonzalez et al., 2001) . Even though sequencing confirmed the presence of only the Y590D mutation in the input inoculum, when PCR amplification products from the env gene from the blood of the infected animals were sequenced, in all cases they showed sequences corresponding to wild-type JSRV env and not the Y590D mutant. One possible explanation could be contamination during the PCR amplification, even though results were only considered when appropriate preparation and PCR control samples were negative. Another explanation could be that the Y590D mutant virus was defective for replication in vivo and there was in vivo selection for reversion of the Y590D mutation to wild-type Env. However, PCR from Y590D-infected lambs yielded wild-type Env even in blood taken 1 day post-infection. This seems too short a time for the appearance of wild-type revertants. Thus contamination during the PCR amplification must be seriously considered although we cannot rule out infection by wild type JSRV of some of our housed sheep although no OPA cases have been recorded in the flock since it was purchased 7 years ago.
To try to find conclusive evidence of infection with JSRV TMY590D, samples of mediastinal lymph node (MLN) collected at post mortem examination were tested by PCR for the presence of JSRV. None of 20 TMY590D-inoculated animals tested contained detectable JSRV in MLN samples. Taken together with the PCR amplifications on infected animal blood, there was no evidence for infection in vivo by JSRV TMY590D.
In vivo infection with JSRV Δorf X In the second experiment, ten newborn lambs were inoculated intratracheally with wild-type JSRV (stock JS21-04) and twelve animals were inoculated with JSRV Δorf X (stock Δorf X-04) ( Table 1 ). The clinical pictures of both groups were very similar. Early clinical signs were first noted in both groups at around 7 weeks of age. All the animals were culled over the next 8 weeks as clinical signs became more noticeable. The last animals were culled at 15 weeks p.i. Histopathology confirmed OPA in all 10 JSRV 21 -inoculated animals and in 11 of the 12 animals inoculated with JSRV Δorf X. There was no discernable difference in the pathology caused by the two viruses (Fig. 3) . Lung fluid was collected at post mortem from 7 of the 12 animals inoculated with JSRV Δorf X, and 7 of the 10 inoculated with JSRV 21 . The volumes collected varied from 2 to 40 ml. By comparison, lung fluid collection from naturally occurring field cases of OPA may be from 0 to 500 ml of lung fluid per day. Large volumes of lung fluid are generally associated with more extensive tumor lesions, while the experimentally inoculated animals typically had multiple small lesions.
To test if the inoculated JSRV Δorf X mutant virus itself had induced disease and was being produced by the tumor, RNAs from lung fluids from two animals inoculated with this virus were extracted and amplified by RT-PCR. Sequencing of the amplicons indicated the presence of both mutations in the JSRV Δorf X virus ( Table 2) . As expected, equivalent analysis of lung fluids from two animals inoculated with wild-type JSRV 21 showed the predicted wild-type sequences. These results therefore indicate that mutation of the orf X reading frame does not interfere with either in vivo replication or oncogenesis by JSRV.
Comparative quantitation of the inocula used for the in vivo experiments is shown in Fig. 2 and a summary of the outcome of these inoculations is shown in Table 1 .
Discussion
In the studies reported here, we tested for the first time the biological activities of JSRV mutants in vivo in their native host, the sheep. These experiments were facilitated by the isolation of an infectious molecular clone of JSRV (JSRV 21 ), and development of the transient transfection approach for recovering infectious virus (Palmarini et al., 1999a) . Given the logistic and cost challenges of performing in vivo experiments on large animals, the use of an in vitro infectivity assay as a preliminary screen for replicative ability of viral mutants was also important. These experiments describe in vivo tests of JSRV mutants in the YXXM motif in the cytoplasmic tail of the envelope TM protein (important for efficient transformation or rodent cells in vitro), and in the orf X reading frame that is conserved among all JSRV isolates but for which a function has not been assigned.
In the first experiment, we tested if mutation of the TM cytoplasmic tail YXXM motif led to loss of tumorigenesis for JSRV, as might be predicted from the in vitro transformation experiments. Indeed, lambs inoculated with JSRV TMY590D did not develop OPA, which would be consistent with this hypothesis. The Y590D mutant was selected because in the in vitro infection assay, it showed replication equivalent to wildtype JSRV while the Y590F mutant showed a replication defect. If animals infected with JSRV TMY590D showed evidence for infection but no tumors, this would have strongly supported the importance of the YXXM motif in the TM cytoplasmic tail in lung tumorigenesis. The input inoculum was confirmed to contain the Y590D mutation but the only virus that could be detected in these animals was of wild-type sequence and it is therefore questionable whether this represents genuine infection. Reversion would be relatively feasible, since the Y590D mutation was due to a single base change, but wild type sequence was detected as early as day 1 p.i., so sample contamination during the PCR must be strongly considered. A possible explanation for our inability to detect virus with the Y590D mutation in these animals is that it did not efficiently replicate in vivo. As shown in Fig. 2 , the amount of Y590D virus produced from transiently transfected 293T cells was substantially less than from cells producing wild-type virus. This would be consistent with a replication defect in vivo, even though within the limits of the assay, the in vitro infectivity assay did not indicate a defect. In the related betaretrovirus Mason-Pfizer monkey virus (MPMV), the cytoplasmic tail of TM contains a tyrosine residue in the analogous location to the Y590 for JSRV TM, and mutation of the MPMV tyrosine results in defects in transport/release of cytoplasmic viral core particles from the cells (Blot et al., 2006) At the very least, the experiments with JSRV TMY590D indicate that the Y590 residue is essential for tumorigenesis and/or replication of JSRV. It may be that cell transformation or enhanced cell division is necessary for efficient production and spread of JSRV. In the future it might be interesting to test other non-transforming TM cytoplasmic tail mutants to see if they are not tumorigenic. We have carried out alanine scanning mutagenesis of the cytoplasmic tail, and identified quite a number that do not transform cells in vitro (Hull and Fan, 2006) . We have generated pCMV2JS21 plasmids containing each of these mutations and found that the majority of them (unlike JSRV TMY590D) produce the same amounts of virus during transient transfections of 293T cells. It will be interesting to test if any of the JSRVs with non-transforming mutations in the TM cytoplasmic tail show replication equivalent to wild-type JSRV in the in vitro infection of CP cells. If a mutant with a non-transforming env gene shows normal levels of virus production and replication in vitro, it is possible that such a mutant would show in vivo replication but no tumorigenesis. We also identified alanine substitutions in the TM cytoplasmic tail that showed enhanced transformation in vitro (Hull and Fan, 2006) . It would be interesting to investigate if such mutants show enhanced tumorigenicity in animals.
The goal of the in vivo test of JSRV TMY590D was to determine if the JSRV Env protein is functioning as an oncogene in JSRV-induced OPA. After these experiments were initiated, two experiments have strongly confirmed this hypothesis. Wootton et al. (2005) showed that infection of immunodeficient mice with an adeno-associated virus (AAV)based vector expressing the JSRV Env protein developed lung adenocarcinomas with histopathology reminiscent of OPA. In addition, we generated a JSRV-based vector expressing only the Env protein, and showed that inoculation of the vector into newborn lambs resulted in development of OPA (Caporale et al., 2006) .
The experiment with JSRV Δorf X showed that this virus induced OPA with a similar time course and histopathology compared to wild-type JSRV (Fig. 3) . This confirmed the indications from the in vitro experiments that orf X is not required for in vivo replication or transformation by JSRV. However, it was still possible that a truncated orf X protein could be contributing to these processes, since JSRV Δorf X could in principle encode a protein of 85aa. The mutations were chosen as these were sites where stop codons could be introduced into orf X without altering the amino acid sequence of the overlapping pol gene. Interestingly, ovine enzootic nasal tumor virus (ENTV-1) has stop codons in exactly the same places as those engineered into JSRV Δorf X (Cousens et al., 1999) . These experiments provided the first large-scale evaluation of the in vivo tumorigenicity of molecularly cloned JSRV. Originally, induction of JSRV-induced OPA employed JSRV inocula derived from concentrated lung fluids from animals with OPA (Martin et al., 1976; Salvatori et al., 2004; Summers et al., 2002 Summers et al., , 2005 . These previous studies showed induction of OPA within weeks-to-months, although in some cases induction of disease has been less efficient (J.M. Sharp, personal communication). In a previous infection with cloned JSRV 21 , 2 out 4 animals developed OPA after 4 months (Palmarini et al., 1999a) . This might have suggested that the cloned JSRV was less oncogenic or infectious than lung fluid-derived JSRV. Therefore in the first experiment described here, 20 animals were infected with wild-type JSRV 21 as the positive control. As described, 17/20 of the JSRV 21 -inoculated lambs developed OPA. Consequently, in the second experiment, a reduced number of animals were infected with JSRV 21 or JSRV Δorf X. Combining the results with JSRV 21 in the first and second experiments, it can be predicted that 92.5 ± 10.6% of animals (at least of the age and breed utilized in this study) will develop OPA when inoculated with the concentration of JSRV 21 used here under these experimental conditions. Although quantification of viral RNA in the inocula did not necessarily measure infectious virus, it appeared to be a reasonable way of equalizing virus dose within and between experiments. The results from these large scale in vivo experiments will allow better predictions of outcomes in future studies, resulting in using smaller groups of animals while maintaining statistical power, in line with the aims of the 3Rs in animal experimentation (Flecknell, 2002; Russell and Burch, 1959) .
Post mortem examinations showed that OPA tumors with discrete lesions had developed in the wild-type and JSRV Δorf X-inoculated animals within a few weeks of infection. On the other hand, two animals suspected of having early physical symptoms of OPA did not show evidence of tumors by histopathology. This may have been because we were looking for subtle early signs of OPA which may be similar to symptoms of other lung infections. A recent field study also found that it was not possible to identify early stage OPA from clinical signs, and even late stage OPA may be misdiagnosed prior to postmortem examination (Cousens et al., in press) .
In summary, this study demonstrated the efficacy of the JSRV 21 experimental OPA system as a model to test JSRV pathogenicity in vivo. We showed that a complete orf X is not required for pathogenesis of JSRV. We also showed that mutation of Y590, part of the YXXM motif of envTM which is predicted to be involved in transformation by JSRV, appears to abrogate the ability of the virus to replicate and/or cause tumors in vivo.
Materials and methods
Vector constructs
Generation of the infectious molecular clone pCMV2JS21 has been described previously (accession number AF105220) (Palmarini et al., 1999a) . The TM mutant, JSRV 21 TM-Y590D, has a single nucleotide substitution changing the tyrosine at position 590 to aspartic acid . The Δorf X mutant of pCMV2JS21 has been described previously ; two T to A substitutions in the orf X region (nt 4565-5104) generate two stop codons in this reading frame (at 4821 TTA to TAA and at 4952 TTA to TAA) without altering the amino acid sequence encoded by the overlapping region of the pol gene.
In vitro virus production
Human 293T cells (3.2 × 10 6 cells per 10 cm plate) in 10 ml of D-MEM/10%FBS/Penicillin/Streptomycin were seeded approximately 24 h before transfection. Cells were transfected with 28 μg per plate pCMV2JS21 (Palmarini et al., 1999a) using the CalPhos Mammalian Transfection Kit (Clontech) as per manufacturer's instructions. After 12 h the transfection medium was replaced with 5 ml culture medium. Culture medium was harvested 24, 48 and 72 h later. At each time point the supernatant was filtered (0.45 μM filters) and virus was concentrated by centrifugation (100,000 g for 1 h at 4°C) on 50% and 25% glycerol cushions as described previously (Palmarini et al., 1999a) . Pellets were resuspended in 0.1 M NaCl, 0.01 M Tris (pH 7.5), 1 mM EDTA (one hundredth original volume) and stored at − 70°C. Immediately prior to inoculation the concentrated stocks were pooled and adjusted to 66 ml with PBS.
In vitro infection
Sheep choroid plexus cells (CP-1) were infected with wildtype or Δorf X mutant JSRV produced from transfected 293T cells as described previously (Palmarini et al., 1999a) . In parallel, virus that had been heat-inactivated (15 min at 65°C) was also infected into CP-1 cells. The infected cell cultures were serially passaged, and at different passages were DNA from cell extracts was tested for the presence of exogenous JSRV DNA by PCR employing primers P-I (TGGGAGCTCTTTGGCAA-AAGCC) and P-III (CACCGGATTTTTACACAATCACCGG) (Palmarini et al., 1996) .
Experimental infection JSRV TMY590D
One to 7-day-old lambs from a known OPA-free flock were inoculated with 5 ml of virus stock by the intratracheal route. Twenty lambs each received the equivalent of ten 10 cm plates per animal (all 3 harvests) of JSRV 21 . Twenty lambs each received equivalent amounts of JSRV 21 TMY590D based on western blots for viral CA protein. Aliquots of the inocula were stored at − 70°C for subsequent analysis.
Animals were monitored every 2-3 days for early signs of OPA by observing respiration at rest and after exercise. Signs of abnormal breathing and/or slow recovery time were noted. Animals were euthanized when early OPA was suspected or at 6 or 10 months old. Blood samples were collected at 1 day, 1 week and 1 month post infection and at monthly intervals thereafter. Samples of blood, lung fluid (if present), lung tumor, normal and mediastinal lymph node were collected at necropsy for histopathological examination and/or for PCR analysis.
When available, lung fluid was collected by raising the animal's rear end and collecting the fluid dripping from its nostrils. The lung fluid was prepared as follows: mucus was removed by filtering through sterile gauze and cells and debris were removed by centrifuging 1 ml aliquots in a microfuge for 5 min, discarding the pellet and repeating the microcentrifugation. 100 μl aliquots of clarified lung fluid were stored at − 70°C.
JSRVΔorf X
Two to 4-day-old lambs from a known OPA-free flock were inoculated with 5 ml of in vitro produced virus by the intratracheal route. 10 lambs received the equivalent of seven and a half 10 cm plates (all 3 harvests) of JSRV21. Twelve lambs received JSRV21Δorf X harvested from nine plates. Aliquots of the inocula were stored at − 70°C for subsequent analysis. Animals were monitored and lung fluid was collected as above.
PCR on lymph nodes
The QIAgen tissue kit was used (as manufacturer's instructions) to extract DNA from lymph nodes collected at post mortem. PCR tests were performed in triplicate as previously described (Salvatori et al., 2004) . PCR conditions were as follows: 100 ng of test DNA with 5 μl of 10× PCR Buffer (Qiagen), 200 μM dNTPs (Roche Diagnostics Ltd., East Sussex, UK), 200 μM of each primer P-I and P-III and 1.25 U of Hot Start Taq polymerase (Qiagen) in a final volume of 50 μl. Cycle conditions were 94°C for 16 min, followed by 35 cycles at 94°C for 30 s, 59°C for 30 s and 72°C for 30 s, with a final extension step of 5 min at 72°C. PCR products were visualized following electrophoresis in a 2% agarose gel containing 100 μg ml ethidium bromide. If any one of the triplicate reactions generated a product of the correct size the test was considered JSRV positive.
Quantitation of the inocula
The viral RNA copy numbers in the inocula were compared using quantitative real-time PCR (Cousens et al., in preparation) . Briefly, virus was prepared using the QIAgen viral RNA kit according to the manufacturer's instructions and eluting with 100 μl of elution buffer. Single step RT-PCR was conducted as follows using reagents from the Applied Biosystems real-time one step RT-PCR kit; (1× reaction buffer, 1× RT, 10 μM each dNTP), plus 200 nM each primer P-I and P-III, 200 nM fluorogenic probe JS-T (5′-FAM-AGCAAACATCCGARCCT-TAAGAGCTTTCAAAA-TAMRA-3′), and 4 μl of test or standard RNA template in a 50 μl reaction volume. Amplification, data analysis and data acquisition were carried out on an ABI Prism SDS 7000 (Applied Biosystems). Cycling conditions were as follows: 48°C for 30 min, 94°C for 10 min followed by 40 cycles of 95°C for 15 s, 59°C for 30 s and 60°C for 30 s.
Sequence analysis of inocula and experimental samples
RT-PCR followed by sequencing was used to check the sequence of JSRV in the inocula and in virus produced in lung fluid of the animals with OPA. Fifty microlitres of clarified lung fluid or of inoculum was treated with DNase as follows: 0.1 mM sodium acetate, 2.5 mM MgCl 2 5 mM Tris pH 8.5, 2 μl DNase (RNase free) (Roche) in a total volume of 140 μl, incubated at 30°C for 1 h then 65°C for 10 min. RNA was then extracted using the QIAgen viral RNA kit according to the manufacturer's instructions and eluted in 50 μl. Four microliters of RNA was used for RT-PCR as described below. The product was gel purified and recovered using the QIAgen gel purification kit according to the manufacturer's instructions. Sequencing was done on a MegaBACE 500 using ET terminator chemistry. The data were processed using the Cimarron 3.12 basecaller.
JSRV TMY590F PCR
Hemi-nested PCR was conducted using primers TMfo (7004-7034 JSRV21) AAGATGAGAGTTGAAATGCTGCA-TATG and TMr (complement of 7225-7247) GTAGGAATAC-TTGTGTTTATTATAATTGTCG in the first round and TMfi (7086-7101 JSRV 21) GTAYTTGTCCTAGGCTTTGGCTT and TMr in the second round, to amplify the region of JSRV containing the Y590D substitution. Reaction conditions were 1× reaction buffer (QIAgen) plus 0.5 mM MgCl 2 , 0.2 mM each dNTP, plus 200 nM each primer in a 50 μl reaction volume. Cycling conditions were as follows: 48°C for 30 min, 94°C for 10 min followed by 35 cycles of 95°C for 30 s, 57°C for 30 s and 72°C for 60 s, with a final extension of 5 min at 72°C. A number of the amplimers were sequenced. These were generated in separate RT-PCR runs from at least 2 independent DNA extractions for each sample and were sequenced individually.
To check the sequence of the JSRV TMY590D inoculum RT-PCR was conducted using primers TMf1 and TMr with the onestep Superscript III RT-PCR kit (Invitrogen) according to the manufacturer's instructions, and 4 μl of RNA as target. Cycles were; 50°C 15 min, 95°C 2 min then 35 cycles of 95°C 15 s, 57°C 30 s.
orf X PCR
DNA fragments spanning the orf X mutations were generated with primers orf X-f1 TCTGGCAAACAGATGTTACTCAC (4777-4797 of JSRV 21 ) and orf X-r2 GGCTAGTATACCCA-GGTCC (C' of 4966-4984) using the one-step Superscript III RT-PCR kit (Invitrogen) according to the manufacturer's instructions, and 4 μl of RNA as target. Cycles were as follows: 50°C 15 min, 95°C 2 min then 35 cycles of 95°C 15 s, 58°C 30 s.
